TN2010000131A1 - Polo-like kinase inhibitors - Google Patents

Polo-like kinase inhibitors

Info

Publication number: TN2010000131A1
Authority: TN; Tunisia
Prior art keywords: polo; compounds; kinase inhibitors; methods; kinases
Prior art date: 2007-09-25

Application number

TNP2010000131A

Other languages

English (en)

Inventor

Sheldon X Cao

Victoria Feher

Takashi Ichikawa

Benjamin Jones

Stephen W Kaldor

Andre A Kiryanov

Yan Liu

Christopher Mcbride

Srinivasa Reddy Natala

Zhe Nie

Jeffrey A Stafford

Betty Lam

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-25

Filing date

2010-03-22

Publication date

2011-09-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40219644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000131(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-03-22 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2011-09-26 Publication of TN2010000131A1 publication Critical patent/TN2010000131A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Toxicology (AREA)
Transplantation (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

TNP2010000131A 2007-09-25 2010-03-22 Polo-like kinase inhibitors TN2010000131A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US97512707P	2007-09-25	2007-09-25
US3730308P	2008-03-17	2008-03-17
PCT/US2008/077558 WO2009042711A1 (fr)	2007-09-25	2008-09-24	Inhibiteurs de kinase de type polo

Publications (1)

Publication Number	Publication Date
TN2010000131A1 true TN2010000131A1 (en)	2011-09-26

Family

ID=40219644

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2010000131A TN2010000131A1 (en)	2007-09-25	2010-03-22	Polo-like kinase inhibitors

Country Status (26)

Country	Link
US (4)	US8026234B2 (fr)
EP (3)	EP2564850B1 (fr)
JP (2)	JP5372939B2 (fr)
KR (2)	KR101444924B1 (fr)
CN (2)	CN103122001A (fr)
AR (1)	AR071729A1 (fr)
AU (1)	AU2008304417B2 (fr)
BR (1)	BRPI0817315A2 (fr)
CA (2)	CA2699607A1 (fr)
CL (1)	CL2008002852A1 (fr)
CO (1)	CO6270231A2 (fr)
CR (1)	CR11370A (fr)
DO (1)	DOP2010000091A (fr)
EA (1)	EA019487B1 (fr)
EC (1)	ECSP10010129A (fr)
ES (1)	ES2488966T3 (fr)
GE (1)	GEP20125704B (fr)
MA (1)	MA31763B1 (fr)
MX (2)	MX2010003249A (fr)
MY (1)	MY152283A (fr)
NZ (1)	NZ584760A (fr)
PE (1)	PE20090710A1 (fr)
TN (1)	TN2010000131A1 (fr)
TW (1)	TWI436769B (fr)
WO (2)	WO2009042711A1 (fr)
ZA (1)	ZA201002543B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20080095902A (ko)	2006-02-14	2008-10-29	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제의 억제제로서 유용한 디하이드로디아제핀
NZ584760A (en) *	2007-09-25	2012-03-30	Takeda Pharmaceutical	Polo-like kinase inhibitors
EP2610256B1 (fr) *	2007-09-28	2016-04-27	Cyclacel Limited	Dérivés de pyrimidine en tant qu'inhibiteurs de kinase de protéine
EP2303889A1 (fr)	2008-06-18	2011-04-06	F. Hoffmann-La Roche AG	Pyrimidodiazépines à substitution halogéno en tant qu inhibiteurs de plkl
WO2010114902A1 (fr) *	2009-03-31	2010-10-07	Arqule, Inc.	Composés tétrahydropyrazolo-pyrido-azépine substitués
CA2756568C (fr)	2009-04-06	2018-02-13	University Health Network	Inhibiteurs de kinases et procede de traitement du cancer avec ceux-ci
NZ599342A (en)	2009-09-25	2014-04-30	Vertex Pharma	Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
AU2010299579A1 (en)	2009-09-25	2012-05-03	Vertex Pharmaceuticals Incorporated	Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
JP2013515734A (ja)	2009-12-23	2013-05-09	エランファーマシューティカルズ，インコーポレイテッド	ポロ様キナーゼの阻害薬としてのプテリジノン
PT2556071T (pt)	2010-04-06	2016-11-22	Univ Health Network	Inibidores de quinase e seus usos no tratamento de cancro
TW201307347A (zh)	2010-11-01	2013-02-16	Arqule Inc	經取代苯並－咪唑並－吡啶並－二氮呯化合物
JP5986566B2 (ja) *	2011-07-07	2016-09-06	イハラケミカル工業株式会社	ニトロベンゼン化合物の製造方法
WO2013058344A1 (fr) *	2011-10-21	2013-04-25	武田薬品工業株式会社	Procédé de prédiction de l'effet d'un inhibiteur de plk1
PT3057965T (pt)	2013-10-18	2019-04-23	Univ Health Network	Formas de sal e cristal de inibidor de plk-4
JP2017504651A (ja)	2014-01-31	2017-02-09	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	ジアゼパン誘導体の使用
KR20160115953A (ko)	2014-01-31	2016-10-06	다나-파버 캔서 인스티튜트 인크.	디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
JP2017526741A (ja)	2014-08-08	2017-09-14	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	ジアゼパン誘導体およびその使用
WO2016201370A1 (fr)	2015-06-12	2016-12-15	Dana-Farber Cancer Institute, Inc.	Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
PE20181287A1 (es)	2015-09-11	2018-08-07	Dana Farber Cancer Inst Inc	Ciano tienotriazolpirazinas y usos de las mismas
HK1256419A1 (zh)	2015-09-11	2019-09-20	达纳-法伯癌症研究所股份有限公司	乙酰胺噻吩並三唑並二氮雜環庚三烯及其用途
SG10201913450PA (en)	2015-11-25	2020-03-30	Dana Farber Cancer Inst Inc	Bivalent bromodomain inhibitors and uses thereof
TWI844006B (zh) *	2016-05-05	2024-06-01	美商嘉來克生命科學有限責任公司	整合應激途徑之調節劑
BR112021021106A2 (pt)	2019-04-24	2021-12-14	Univ Health Network	Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona
US20230158158A1 (en) *	2020-03-27	2023-05-25	Uppthera	Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1
WO2022145989A1 (fr) *	2020-12-31	2022-07-07	(주) 업테라	Dérivé de pyrimidodiazépine servant d'inhibiteur sélectif de plk1
CN116761806B (zh) *	2021-02-08	2025-10-10	上海复星医药产业发展有限公司	5，6-二氢噻吩并[3，4-h]喹唑啉类化合物
TW202508595A (zh)	2023-05-04	2025-03-01	美商銳新醫藥公司	用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (fr)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Rmc-6291 destiné à être utilisé dans le traitement d'une maladie ou d'un trouble lié à une protéine ras
WO2025080946A2 (fr)	2023-10-12	2025-04-17	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2025171296A1 (fr)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Inhibiteurs de ras
WO2025240847A1 (fr)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Inhibiteurs de ras

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3710795A (en)	1970-09-29	1973-01-16	Alza Corp	Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en)	1972-04-20	1977-08-23	Allen & Hanburys Limited	Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en)	1972-04-20	1976-03-24	Allen & Hanburys Ltd	Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en)	1972-12-08	1976-05-18	Syntex (U.S.A.) Inc.	Dialkylated glycol compositions and medicament preparations containing same
US4410545A (en)	1981-02-13	1983-10-18	Syntex (U.S.A.) Inc.	Carbonate diester solutions of PGE-type compounds
US4328245A (en)	1981-02-13	1982-05-04	Syntex (U.S.A.) Inc.	Carbonate diester solutions of PGE-type compounds
US4358603A (en)	1981-04-16	1982-11-09	Syntex (U.S.A.) Inc.	Acetal stabilized prostaglandin compositions
US4409239A (en)	1982-01-21	1983-10-11	Syntex (U.S.A.) Inc.	Propylene glycol diester solutions of PGE-type compounds
WO2001019825A1 (fr)	1999-09-15	2001-03-22	Warner-Lambert Company	Pteridinones utilisees comme inhibiteurs de kinases
AU7491400A (en)	1999-09-17	2001-04-17	Abbott Gmbh & Co. Kg	Kinase inhibitors as therapeutic agents
NZ531928A (en)	2001-09-04	2005-10-28	Boehringer Ingelheim Pharma	Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
US6806272B2 (en) *	2001-09-04	2004-10-19	Boehringer Ingelheim Pharma Kg	Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US6861422B2 (en) *	2003-02-26	2005-03-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060074088A1 (en)	2004-08-14	2006-04-06	Boehringer Ingelheim International Gmbh	Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (fr) *	2004-08-25	2006-03-01	Boehringer Ingelheim Pharma GmbH & Co.KG	Dihydropteridinones, procédés de préparation et leur utilisation en tant que médicaments
EP1632493A1 (fr) *	2004-08-25	2006-03-08	Boehringer Ingelheim Pharma GmbH & Co.KG	Dérivés de dihydropteridine, méthodes de préparation et utilisation en tant que médicament
JP2008510771A (ja) *	2004-08-27	2008-04-10	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用
KR20080095902A (ko)	2006-02-14	2008-10-29	버텍스 파마슈티칼스 인코포레이티드	단백질 키나제의 억제제로서 유용한 디하이드로디아제핀
WO2007135374A1 (fr)	2006-05-19	2007-11-29	Astrazeneca Ab	Composés de dihydroptéridine en tant qu'agents antiprolifératifs
TW200808325A (en) *	2006-07-06	2008-02-16	Astrazeneca Ab	Novel compounds
PT2139892E (pt)	2007-03-22	2011-11-21	Takeda Pharmaceutical	Pirimidodiazepinas substituídas úteis como inibidores da plk1
EP2190849B1 (fr)	2007-08-15	2013-11-20	Vertex Pharmceuticals Incorporated	Dérivés 4-(9-(3,3-difluorocyclopentyl)-5,7,7-triméthyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazépin-2-ylamino)-3-méthoxybenzamide en tant que inhibiteurs des protéines kinases humaines plk1 a plk4 pour le traitement de maladies prolifératives
NZ584760A (en) *	2007-09-25	2012-03-30	Takeda Pharmaceutical	Polo-like kinase inhibitors
EP2610256B1 (fr)	2007-09-28	2016-04-27	Cyclacel Limited	Dérivés de pyrimidine en tant qu'inhibiteurs de kinase de protéine
EP2303889A1 (fr) *	2008-06-18	2011-04-06	F. Hoffmann-La Roche AG	Pyrimidodiazépines à substitution halogéno en tant qu inhibiteurs de plkl

2008
- 2008-09-24 NZ NZ584760A patent/NZ584760A/en not_active IP Right Cessation
- 2008-09-24 KR KR1020107009029A patent/KR101444924B1/ko not_active Expired - Fee Related
- 2008-09-24 JP JP2010526067A patent/JP5372939B2/ja not_active Expired - Fee Related
- 2008-09-24 US US12/237,306 patent/US8026234B2/en not_active Expired - Fee Related
- 2008-09-24 CA CA2699607A patent/CA2699607A1/fr not_active Abandoned
- 2008-09-24 GE GEAP200811771A patent/GEP20125704B/en unknown
- 2008-09-24 AU AU2008304417A patent/AU2008304417B2/en not_active Ceased
- 2008-09-24 EP EP12189293.9A patent/EP2564850B1/fr active Active
- 2008-09-24 US US12/680,183 patent/US20110201818A1/en not_active Abandoned
- 2008-09-24 MY MYPI20101261 patent/MY152283A/en unknown
- 2008-09-24 MX MX2010003249A patent/MX2010003249A/es active IP Right Grant
- 2008-09-24 ES ES08834219.1T patent/ES2488966T3/es active Active
- 2008-09-24 BR BRPI0817315 patent/BRPI0817315A2/pt not_active IP Right Cessation
- 2008-09-24 CN CN2012105686507A patent/CN103122001A/zh active Pending
- 2008-09-24 EA EA201070395A patent/EA019487B1/ru not_active IP Right Cessation
- 2008-09-24 WO PCT/US2008/077558 patent/WO2009042711A1/fr not_active Ceased
- 2008-09-24 EP EP08834219.1A patent/EP2205241B1/fr active Active
- 2008-09-24 CN CN2008801169537A patent/CN101917995A/zh active Pending
- 2008-09-24 KR KR1020147017278A patent/KR20140097440A/ko not_active Ceased
- 2008-09-25 CA CA2700295A patent/CA2700295A1/fr not_active Abandoned
- 2008-09-25 CL CL2008002852A patent/CL2008002852A1/es unknown
- 2008-09-25 TW TW097137049A patent/TWI436769B/zh not_active IP Right Cessation
- 2008-09-25 JP JP2010526073A patent/JP2010540464A/ja active Pending
- 2008-09-25 WO PCT/US2008/077746 patent/WO2009042806A1/fr not_active Ceased
- 2008-09-25 US US12/680,142 patent/US8202990B2/en not_active Expired - Fee Related
- 2008-09-25 PE PE2008001672A patent/PE20090710A1/es not_active Application Discontinuation
- 2008-09-25 EP EP08833760A patent/EP2197442B1/fr not_active Not-in-force
- 2008-09-25 MX MX2010003244A patent/MX2010003244A/es active IP Right Grant
- 2008-09-25 AR ARP080104179A patent/AR071729A1/es unknown
2010
- 2010-03-22 TN TNP2010000131A patent/TN2010000131A1/fr unknown
- 2010-03-25 DO DO2010000091A patent/DOP2010000091A/es unknown
- 2010-04-08 MA MA32753A patent/MA31763B1/fr unknown
- 2010-04-09 CO CO10041197A patent/CO6270231A2/es active IP Right Grant
- 2010-04-12 ZA ZA2010/02543A patent/ZA201002543B/en unknown
- 2010-04-14 CR CR11370A patent/CR11370A/es unknown
- 2010-04-23 EC EC2010010129A patent/ECSP10010129A/es unknown
- 2010-12-07 US US12/962,557 patent/US8318727B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2700295A1 (fr)	2009-04-02
US8026234B2 (en)	2011-09-27
PE20090710A1 (es)	2009-07-15
MX2010003249A (es)	2010-11-09
WO2009042711A4 (fr)	2009-06-04
KR20140097440A (ko)	2014-08-06
EP2197442B1 (fr)	2012-09-12
AU2008304417B2 (en)	2013-07-18
WO2009042806A1 (fr)	2009-04-02
EP2197442A1 (fr)	2010-06-23
CL2008002852A1 (es)	2009-03-27
AU2008304417A1 (en)	2009-04-02
EP2564850B1 (fr)	2014-08-13
TW200927135A (en)	2009-07-01
US20110201818A1 (en)	2011-08-18
ECSP10010129A (es)	2010-06-29
AR071729A1 (es)	2010-07-14
ES2488966T3 (es)	2014-09-01
US20100222575A1 (en)	2010-09-02
US20110082111A1 (en)	2011-04-07
CN103122001A (zh)	2013-05-29
US20090281092A1 (en)	2009-11-12
KR20100087292A (ko)	2010-08-04
GEP20125704B (en)	2012-12-10
CR11370A (es)	2010-07-16
BRPI0817315A2 (pt)	2015-03-17
ZA201002543B (en)	2011-11-30
US8318727B2 (en)	2012-11-27
EA201070395A1 (ru)	2010-10-29
EP2564850A1 (fr)	2013-03-06
CN101917995A (zh)	2010-12-15
EP2205241A1 (fr)	2010-07-14
EP2205241B1 (fr)	2014-05-21
TWI436769B (zh)	2014-05-11
KR101444924B1 (ko)	2014-10-07
DOP2010000091A (es)	2010-07-31
JP2010540464A (ja)	2010-12-24
HK1145144A1 (en)	2011-04-08
JP5372939B2 (ja)	2013-12-18
WO2009042711A1 (fr)	2009-04-02
NZ584760A (en)	2012-03-30
CA2699607A1 (fr)	2009-04-02
MY152283A (en)	2014-09-15
US8202990B2 (en)	2012-06-19
MX2010003244A (es)	2010-04-21
JP2010540463A (ja)	2010-12-24
CO6270231A2 (es)	2011-04-20
EA019487B1 (ru)	2014-04-30
MA31763B1 (fr)	2010-10-01

Publication	Publication Date	Title
TN2010000131A1 (en)	2011-09-26	Polo-like kinase inhibitors
MY150542A (en)	2014-01-30	Cmet inhibitors
TN2009000249A1 (en)	2010-10-18	Mapk/erk kinase inhibitors
WO2007117995A3 (fr)	2008-01-10	Inhibiteurs de kinase
WO2009146034A3 (fr)	2010-07-15	Inhibiteurs de kinases mapk/erk et procédés d’utilisation de ceux-ci
MY146989A (en)	2012-10-15	Kinase inhibitors
WO2008116107A3 (fr)	2009-03-19	Activateurs de glucokinase
WO2008079787A8 (fr)	2009-07-16	Activateurs de glucokinase
MY152749A (en)	2014-11-28	Pyrazole and fused pyrazole glucokinase activators
WO2007104034A3 (fr)	2008-02-28	Activateurs de la glucokinase
WO2008115890A3 (fr)	2009-04-30	Inhibiteurs de mapk/erk kinase
PT2470546E (pt)	2013-10-14	Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
ATE479687T1 (de)	2010-09-15	Kinaseinhibitoren
WO2007143434A3 (fr)	2008-07-03	Activateurs de glucokinase
MX339476B (es)	2016-05-27	Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
MY150596A (en)	2014-01-30	Hsp90 inhibitors
MX2009010595A (es)	2009-10-22	Derivados de pirrolopirimidina.
JO2822B1 (en)	2014-09-15	Inhibitors of the enzyme kinase P70 S6 and AKT
WO2010111626A3 (fr)	2010-11-18	Inhibiteurs de la poly(adp-ribose)polymérase (parp)
MX341456B (es)	2016-08-18	Amino-quinolinas como inhibidores de cinasa.
WO2008054956A3 (fr)	2008-09-04	Inhibiteurs de kinases
WO2009129401A8 (fr)	2009-12-17	Inhibiteurs de kinases
WO2008045834A3 (fr)	2008-07-24	Inhibiteurs de kinases
WO2008089005A3 (fr)	2009-01-15	Inhibiteurs de rénine
TN2009000130A1 (en)	2010-10-18	Kinase inhibitors